Stock listing
Frankfurt:1YG0 Mendus AB Aktie
German listing (Frankfurt) of Mendus AB · home listing Stockholm:IMMU
Follow Mendus AB into a list and get an email when it puts out news.
Share price · FWB:1YG0
€0.292 EUR -0.011 (-3.6%)
Close on Nov 20, 2026
- Day range
- €0.287 – €0.292 EURNov 20, 2026
- Market cap
- €18.51M EURAt the close on Nov 20, 2026 · price × 63.48M shares outstanding
- 52-week range
- €0.287 – €0.649 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €32 EURMedian day 0 shares · 54 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:IMMU · Home | 3.50 SEK | -0.10 (-2.8%) | 23,516 | 3.43 | 4.20 | 3.305 | 3.60 | Close on Nov 20, 2026 |
| Frankfurt:1YG0 | €0.292 EUR | -0.011 (-3.6%) | — | €0.287 | €0.292 | €0.287 | €0.303 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:1YG0 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.507 | +0.059 | +13.2% | €0.446 | €0.509 | €0.436 | 0 | |
| €0.448 | -0.007 | -1.5% | €0.451 | €0.452 | €0.444 | 0 | |
| €0.455 | -0.021 | -4.4% | €0.467 | €0.473 | €0.451 | 0 | |
| €0.476 | -0.003 | -0.6% | €0.476 | €0.476 | €0.476 | 0 | |
| €0.479 | +0.005 | +1.1% | €0.484 | €0.484 | €0.475 | 0 | |
| €0.474 | +0.022 | +4.9% | €0.452 | €0.474 | €0.449 | 0 | |
| €0.452 | -0.011 | -2.4% | €0.461 | €0.461 | €0.451 | 0 | |
| €0.463 | -0.010 | -2.1% | €0.463 | €0.463 | €0.463 | 0 | |
| €0.473 | -0.002 | -0.4% | €0.473 | €0.473 | €0.473 | 0 | |
| €0.475 | +0.018 | +3.9% | €0.478 | €0.478 | €0.470 | 0 | |
| €0.457 | +0.012 | +2.7% | €0.457 | €0.457 | €0.457 | 0 | |
| €0.445 | +0.008 | +1.8% | €0.445 | €0.445 | €0.445 | 0 | |
| €0.437 | -0.002 | -0.5% | €0.437 | €0.437 | €0.437 | 0 | |
| €0.439 | -0.024 | -5.2% | €0.447 | €0.448 | €0.439 | 0 | |
| €0.463 | +0.025 | +5.7% | €0.463 | €0.463 | €0.463 | 0 | |
| €0.438 | -0.031 | -6.6% | €0.438 | €0.438 | €0.438 | 0 | |
| €0.469 | -0.003 | -0.6% | €0.469 | €0.469 | €0.469 | 0 | |
| €0.472 | +0.013 | +2.8% | €0.472 | €0.472 | €0.472 | 0 | |
| €0.459 | -0.036 | -7.3% | €0.455 | €0.461 | €0.454 | 0 | |
| €0.495 | -0.001 | -0.2% | €0.495 | €0.495 | €0.495 | 0 | |
| €0.496 | -0.014 | -2.7% | €0.500 | €0.503 | €0.495 | 0 | |
| €0.510 | -0.004 | -0.8% | €0.510 | €0.510 | €0.510 | 0 | |
| €0.514 | -0.011 | -2.1% | €0.514 | €0.514 | €0.514 | 0 | |
| €0.525 | -0.005 | -0.9% | €0.525 | €0.525 | €0.525 | 0 | |
| €0.530 | -0.001 | -0.2% | €0.530 | €0.530 | €0.530 | 0 | |
| €0.531 | -0.007 | -1.3% | €0.546 | €0.547 | €0.530 | 0 | |
| €0.538 | +0.003 | +0.6% | €0.540 | €0.540 | €0.536 | 0 | |
| €0.535 | -0.018 | -3.3% | €0.535 | €0.535 | €0.535 | 0 | |
| €0.553 | -0.003 | -0.5% | €0.553 | €0.553 | €0.553 | 0 | |
| €0.556 | -0.005 | -0.9% | €0.557 | €0.557 | €0.555 | 0 | |
| €0.561 | -0.012 | -2.1% | €0.578 | €0.579 | €0.561 | 0 | |
| €0.573 | +0.007 | +1.2% | €0.573 | €0.573 | €0.573 | 0 | |
| €0.566 | -0.011 | -1.9% | €0.579 | €0.583 | €0.563 | 0 | |
| €0.577 | +0.026 | +4.7% | €0.577 | €0.577 | €0.575 | 0 | |
| €0.551 | +0.011 | +2.0% | €0.551 | €0.551 | €0.551 | 0 | |
| €0.540 | +0.003 | +0.6% | €0.540 | €0.540 | €0.540 | 0 | |
| €0.537 | -0.030 | -5.3% | €0.537 | €0.537 | €0.537 | 0 | |
| €0.567 | -0.021 | -3.6% | €0.567 | €0.567 | €0.567 | 0 | |
| €0.588 | -0.023 | -3.8% | €0.588 | €0.588 | €0.588 | 0 | |
| €0.611 | +0.014 | +2.3% | €0.611 | €0.611 | €0.611 | 0 | |
| €0.597 | -0.047 | -7.3% | €0.597 | €0.597 | €0.597 | 3,000 | |
| €0.644 | +0.012 | +1.9% | €0.644 | €0.644 | €0.644 | 0 | |
| €0.632 | 0.000 | 0.0% | €0.627 | €0.639 | €0.621 | 0 | |
| €0.632 | -0.008 | -1.3% | €0.632 | €0.632 | €0.632 | 0 | |
| €0.640 | 0.000 | 0.0% | €0.640 | €0.640 | €0.640 | 0 | |
| €0.640 | -0.001 | -0.2% | €0.640 | €0.640 | €0.640 | 22 | |
| €0.641 | +0.022 | +3.6% | €0.641 | €0.641 | €0.641 | 0 | |
| €0.619 | +0.006 | +1.0% | €0.619 | €0.619 | €0.619 | 0 | |
| €0.613 | +0.005 | +0.8% | €0.613 | €0.613 | €0.613 | 0 | |
| €0.608 | -0.011 | -1.8% | €0.608 | €0.608 | €0.608 | 0 | |
| €0.619 | +0.020 | +3.3% | €0.619 | €0.619 | €0.619 | 22 | |
| €0.599 | -0.023 | -3.7% | €0.599 | €0.599 | €0.599 | 0 | |
| €0.622 | +0.013 | +2.1% | €0.622 | €0.622 | €0.622 | 0 | |
| €0.609 | +0.013 | +2.2% | €0.609 | €0.609 | €0.609 | 0 | |
| €0.596 | +0.012 | +2.1% | €0.596 | €0.596 | €0.596 | 0 | |
| €0.584 | -0.003 | -0.5% | €0.584 | €0.584 | €0.584 | 0 | |
| €0.587 | -0.007 | -1.2% | €0.587 | €0.587 | €0.587 | 0 |
Splits
1 split · FWB:1YG0 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- Frankfurt:1YG0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Sep 14, 2026
Mendus draws under the second tranche of the Fenja Capital II A/S loan facility, extending cash runway into the second quarter of 2027
Latest earnings call · Aug 20, 2026
Mendus (Stockholm:IMMU) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Nov 11, 2026
Q3 2026 Earnings Presentation
Earnings · 29 slides
Latest news
Mendus draws under the second tranche of the Fenja Capital II A/S loan facility, extending cash runway into the second quarter of 2027
Sep 14, 2026
Closed €0.611 (+2.3%) on Sep 14, 2026
Mendus AB interim report april– June 2026
Aug 20, 2026
Closed €0.587 (-1.2%) on Aug 20, 2026
Invitation to presentation of Mendus' second quarter 2026 financial report and business update
Aug 13, 2026
Closed €0.581 (+2.1%) on Aug 13, 2026
Change in number of shares and votes in Mendus AB (publ)
Jul 31, 2026
Closed €0.647 (+7.1%) on Jul 31, 2026
Mendus AB (publ) has decided on directed issues of Class C shares and transfer of own ordinary shares
Jun 23, 2026
Closed €0.563 (-8.8%) on Jun 24, 2026
Mendus AB (publ) repurchases outstanding warrants from Fenja
Jun 10, 2026
Closed €0.453 (+2.0%) on Jun 11, 2026
Mendus AB (publ) has resolved to transfer own shares
May 27, 2026
Closed €0.526 (+6.5%) on May 28, 2026
Mendus AB Interim Report January – March 2026
May 8, 2026
Closed €0.401 (-7.0%) on May 8, 2026
Invitation to presentation of Mendus' first quarter 2026 financial report and business update
May 1, 2026
Closed €0.453 (+5.6%) on May 4, 2026
Mendus announces first patient enrolled in the VITAL-CML trial
Apr 21, 2026
Closed €0.46 (+3.1%) on Apr 21, 2026
Mendus AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 17 in all · newest Sep 14, 2026 · oldest 2026
- Calls
- 10 calls with a replay · 10 with a transcript · latest Aug 20, 2026
- Decks
- 2 decks · latest Nov 11, 2026
Where Mendus AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:IMMU · Home listing | Stockholm | Sweden | SEK |
| LS Exchange:A40CZ4 | LS Exchange | Germany | EUR |
| gettex:1YG0 | gettex | Germany | EUR |
| Aquis:IMMUS | Aquis | United Kingdom | SEK |
| Aquis:IMMUS | Aquis | United Kingdom | SEK |
| Frankfurt:1YG0 · This page | Frankfurt | Germany | EUR |
| Lang & Schwarz:A40CZ4 | Lang & Schwarz | Germany | EUR |
| Munich:1YG0 | Munich | Germany | EUR |
| Stuttgart:1YG0 | Stuttgart | Germany | EUR |
Valuation
Price/book 0.4× against a median of 1.3×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 180.2M SEK
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Mendus AB · OMXSTO:IMMU | US$21.73M | US$17.63M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | n/a |
| BioNxt Solutions Inc · CSE:BNXT | US$22.78M | US$22.72M | n/a | n/a | n/a | n/a | n/a | n/a | 0.22 |
| Polyrizon Ltd. · NASDAQ:PLRZ | US$22.61M | US$7.56M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.67 |
| ME Therapeutics Holdings, Inc. · CSE:METX | US$22.25M | US$21.88M | n/a | n/a | n/a | 49.5× | n/a | 0.0× | 0.52 |
| CervoMed Inc. · NASDAQ:CRVO | US$22.09M | US$2.49M | n/a | 285× | n/a | 1.3× | n/a | 0.0× | 1.97 |
| Sona Nanotech, Inc. · CSE:SONA | US$21.84M | US$22.06M | n/a | n/a | n/a | n/a | n/a | n/a | 0.47 |
| Metagenomi Therapeutics, Inc. · NASDAQ:MGX | US$21.36M | −US$44.10M | n/a | −6.2× | n/a | 0.2× | n/a | 0.4× | 1.65 |
| NanoGroup SA · GPW:NNG | US$21.31M | US$18.78M | n/a | n/a | n/a | 4.0× | n/a | 0.0× | n/a |
| Cel-Sci Corporation · AMEX:CVM | US$21.28M | US$14.76M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 1.13 |
| ZYUS Life Sciences Corporation · TSXV:ZYUS | US$20.92M | US$25.65M | n/a | 98.4× | n/a | n/a | n/a | n/a | -0.02 |
| Xbrane Biopharma AB · OMXSTO:XBRANE | US$20.86M | US$23.45M | n/a | 1.9× | n/a | 0.4× | −49.0% | 0.1× | n/a |
| Median of the others | US$21.60M | US$20.33M | 50.1× | 1.3× | −49.0% | 0.0× | 0.60 |
Forecasts
Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.
- Price target
- 33.95 SEK · Analysts' mean
- EPS, year to Dec 2026
- -1.45 · 2 analysts
- Revenue, year to Dec 2026
- 15M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Erik Manting | Chief Executive Officer |
| Lotta Ferm | Chief Financial Officer |
| Hans Preusting | Chief Operating Officer |
| Tariq Mughal | Chief Medical and Scientific Officer |
Board
| Director | Role |
|---|---|
| Sven Andreasson | Chairman |
| Dharminder Chahal | Board Member |
| Helén Tuvesson | Board Member |
| José Manuel Ochoa | Board Member |
| Sijmen de Vries | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Mendus (Stockholm:IMMU) Q2 2026 Earnings Call | Thu, Aug 20, 2026 · 8:00 AM ET | Replay |
| Mendus (Stockholm:IMMU) Q1 2026 Earnings Call | Fri, May 08, 2026 · 8:00 AM ET | Replay |
| Mendus (Stockholm:IMMU) Q4 2025 Earnings Call | Wed, Feb 11, 2026 · 8:00 AM ET | Replay |
| Mendus (Stockholm:IMMU) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 4:00 AM ET | Replay |
| Mendus (Stockholm:IMMU) Q2 2025 Earnings Call | Thu, Aug 21, 2025 · 7:00 AM ET | Replay |
| Mendus (Stockholm:IMMU) Q1 2025 Earnings Call | Tue, May 06, 2025 · 8:00 AM ET | Replay |
| Mendus (Stockholm:IMMU) Q4 2024 Earnings Call | Thu, Feb 13, 2025 · 2:30 AM ET | Replay |
| Mendus (Stockholm:IMMU) Q3 2024 Earnings Call | Fri, Nov 08, 2024 · 8:00 AM ET | Replay |
| Mendus (Stockholm:IMMU) Q2 2024 Earnings Call | Fri, Aug 23, 2024 · 4:00 AM ET | Replay |
| Mendus (Stockholm:IMMU) Q1 2024 Earnings Call | Fri, May 17, 2024 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 10, 2026 · After close | −8.6% |
| Q2 2026 | Aug 19, 2026 · After close | −0.1% |
| Q1 2026 | May 8, 2026 | +38.3% |
| Q4 2025 | Feb 11, 2026 · Before open | −3.0% |
| Q3 2025 | Nov 13, 2025 · Before open | +6.1% |
| Q2 2025 | Aug 21, 2025 · Before open | −3.4% |
| Q1 2025 | May 6, 2025 · Before open | −9.7% |
| Q4 2024 | Feb 13, 2025 · Before open | −1.9% |
| Q3 2024 | Nov 8, 2024 · Before open | −2.9% |
| Q2 2024 | Aug 23, 2024 · Before open | −0.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 17, 2024 · Before open | −0.5% |
| Q4 2023 | Feb 14, 2024 · Before open | +1.6% |
| Q3 2023 | Nov 9, 2023 · Before open | +54.0% |
| Q2 2023 | Aug 29, 2023 · Before open | −1.3% |
| Q1 2023 | May 12, 2023 · Before open | −5.3% |
| Q4 2022 | Feb 17, 2023 · Before open | −6.2% |
| Q3 2022 | Nov 11, 2022 · Before open | +0.2% |
| Q2 2022 | Aug 26, 2022 · Before open | −1.1% |
| Q1 2022 | May 10, 2022 · Before open | −2.7% |
| Q4 2021 | Feb 17, 2022 · Before open | −1.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 29 slides | Nov 11, 2026 |
| Q2 2025 Earnings Presentation | Earnings | 28 slides | Aug 21, 2025 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Loan facility with warrants Announced: SEK 30M · Warrants at SEK 7 Buyers: Fenja Capital II A/S (Lender under the SEK 50 million Loan Facility; drawdown of SEK 30 million Tranche 1 requested; receives 1,935,605 warrants of series 2025/2030) | Jan 30, 2026 | US$3.38M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 5.05M | 28.5M | 3.38M | 31.0K | 0 | 16.7M | 0 | 0 | 0 |
| Cost of revenue | 6.29M | 6.52M | 6.30M | 4.85M | 1.85M | 1.77M | 1.64M | 60.0K | 71.2K | 80.8K |
| Gross profit | -6.29M | -6.52M | 28.5M | -1.85M | -1.84M | -1.77M | 15.0M | -60.0K | -71.2K | -80.8K |
| Research and development | 85.1M | 101.1M | 92.7M | 87.0M | 85.8M | 47.9M | 103.1M | 70.9M | 57.8M | 57.8M |
| Selling, general and administrative | 35.2M | 34.1M | 36.8M | 48.9M | 43.5M | 38.1M | 28.5M | 25.6M | 61.5M | 10.2M |
| Operating income | -120.3M | -135.1M | -100.7M | -133.7M | -130.1M | -86.0M | -132.3M | -97.8M | -80.7M | -73.5M |
| Depreciation and amortization | 6.29M | 6.50M | 6.29M | 4.85M | 1.85M | 1.77M | 1.64M | 60.0K | 71.2K | 80.8K |
| EBITDA | -114.0M | -128.6M | -94.4M | -128.8M | -128.2M | -84.3M | -130.7M | -97.8M | -80.6M | -73.4M |
| Interest expense | 3.28M | 1.22M | 3.12M | 5.26M | 3.31M | 3.22M | 17.0K | 14.0K | 273.5K | 0 |
| Income before tax | -113.3M | -128.4M | -101.6M | -138.8M | -133.4M | -89.2M | -134.0M | -97.9M | -80.3M | -73.6M |
| Income tax | -565.0K | 0 | 0 | 0 | 1.69M | -161.1K | -635.8K | -4 | ||
| Net income | -113.3M | -128.4M | -101.6M | -138.8M | -133.4M | -89.2M | -135.7M | -97.9M | -80.3M | -73.6M |
| Earnings per share, basic | -2.17 | -2.64 | -4.39 | -0.64 | -0.67 | -1.08 | -1.69 | -1.75 | -2.85 | -2.62 |
| Earnings per share, diluted | -0.70 | -0.73 | -1.17 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 64.7M | 101.9M | 120.8M | 41.9M | 155.3M | 167.6M | 296.8M | 443.8M | 128.3M | 102.9M |
| Short-term investments | -441.0K | 1.47M | 0 | 9.53M | ||||||
| Receivables | 2.34M | 955.0K | 889.0K | 3.44M | 19.7M | 20.2M | 18.7M | 3.31M | 3.50M | 2.15M |
| Inventory | -3.30M | 1.92M | 10.2M | -12.4M | 1.47M | -3.50M | ||||
| Current assets | 73.1M | 134.0M | 188.4M | 47.2M | 185.2M | 192.6M | 303.6M | 450.4M | 140.8M | 121.4M |
| Property, plant and equipment | 17.0M | 21.1M | 23.2M | 13.9M | 2.11M | 1.71M | 4.33M | 9.00K | 69.0K | 140.4K |
| Goodwill | 108.3M | 108.3M | 108.3M | 108.3M | 108.3M | 108.3M | 0 | |||
| Total assets | 628.3M | 696.4M | 756.0M | 620.4M | 721.0M | 728.7M | 303.8M | 450.4M | 246.1M | 121.6M |
| Accounts payable | 6.66M | 7.60M | 8.13M | 7.41M | 11.6M | 10.4M | 12.8M | 31.3M | 11.7M | 5.04M |
| Current liabilities | 27.1M | 31.3M | 29.3M | 59.4M | 27.6M | 48.3M | 30.2M | 43.5M | 55.7M | 18.3M |
| Long-term debt | 850.0K | 850.0K | 850.0K | 22.8M | 36.7M | 19.0M | 850.0K | 850.0K | 850.0K | 850.0K |
| Total debt | 18.9M | 22.7M | 24.5M | 52.0M | 36.7M | 19.0M | 2.10M | 850.0K | 850.0K | 850.0K |
| Total liabilities | 43.3M | 51.2M | 51.2M | 105.9M | 64.2M | 67.6M | 31.0M | 44.3M | 56.6M | 19.2M |
| Shareholders' equity | 585.1M | 645.1M | 704.7M | 514.4M | 656.7M | 661.1M | 272.8M | 406.0M | 189.6M | 102.4M |
| Shares outstanding | 52.2M | 48.6M | 23.1M | 216.5M | 199.7M | 82.7M | 80.2M | 55.8M | 28.2M | 28.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -81.5M | -79.7M | -162.8M | -109.3M | -138.0M | -56.6M | -145.8M | -104.7M | -46.4M | -33.7M |
| Capital spending | -307.0K | -1.83M | -1.82M | -12.1M | -1.36M | -464.0K | -809.0K | -809.0K | -809.0K | 0 |
| Free cash flow | -81.8M | -81.5M | -164.6M | -121.4M | -139.4M | -57.1M | -146.6M | -104.7M | -46.4M | -33.7M |
| Cash from investing | -734.0K | -1.58M | -442.0K | -12.3M | -1.36M | 157.3M | -251.0K | -809.0K | 10.2M | 25.7M |
| Cash from financing | 45.2M | 61.5M | 242.1M | 8.19M | 127.0M | 50.9M | 756.0K | 419.6M | 62.3M | 16.7M |
| Share buybacks | -1.73M | 69.1M | 321.8M | 0 | 141.2M | 211.4M | 67.8M | 456.3M | 94.8M | 16.7M |
| Change in cash | -37.2M | -18.9M | 78.9M | -113.5M | -12.4M | 151.6M | -147.0M | 314.9M | 26.0M | 70.2M |
Cap table
Built by 6ix from Mendus AB’s releases · as of Jan 30, 2026
- Common shares
- 63,483,415
- Fully diluted
- 63,483,415
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 63,483,415 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 63,483,415 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Dharminder Chahal | Board Member · Since at least Apr 2, 2026 |
| Erik Manting | Chief Executive Officer · Since at least Sep 14, 2026 |
| Hans Preusting | Chief Operating Officer · Since at least Apr 2, 2026 |
| Helén Tuvesson | Board Member · Since at least Apr 2, 2026 |
| José Manuel Ochoa | Board Member · Since at least Apr 2, 2026 |
| Lotta Ferm | Chief Financial Officer · Since at least Nov 4, 2026 |
| Sijmen de Vries | Board Member · Since at least Apr 2, 2026 |
| Sven Andreasson | Chairman · Since at least Apr 2, 2026 |
| Tariq Mughal | Chief Medical and Scientific Officer · Since at least Apr 17, 2026 |
Log in to ask 6ix AI your own questions about Mendus AB.